The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

20 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
32
Autophagy modulation in cancer therapy: Challenges coexist with opportunities.EBI
Sichuan University
17
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.EBI
GlaxoSmithKline
4
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.EBI
University of California
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.EBI
Johann Wolfgang Goethe University
15
MNK, mTOR or eIF4E-selecting the best anti-tumor target for blocking translation initiation.EBI
Shandong University
41
Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.EBI
Sichuan University
26
Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free-Wilson Analysis for Improved In Vivo Efficacy.EBI
Takeda California
36
Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual Screening.EBI
Sichuan University
36
Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.EBI
University of Calabria
33
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors.EBI
Revolution Medicines
20
Research progress of mTOR inhibitors.EBI
Jilin University
103
Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).EBI
University of Hradec Kralove
9
Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability.EBI
University of Basel
4
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.EBI
University of Basel
1
CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model.EBI
Cellzome
19
Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors.EBI
Nestle Skin Health
29
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.EBI
University of Basel
28
Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.EBI
China Pharmaceutical University
6
Imidazopyrazine Derivatives As Inhibitors of mTOR.EBI
Dart Neuroscience
3
Inhibition of mTOR Kinase and Cancer Treatment.EBI
Therachem Research Medilab (India)